Shop

Author at Microdose

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Finance

10 Mar 2022

Albert Labs Begins Trading on the CSE

The psychedelic medicine industry has a new player....

By Jason Najum

Breaking News

9 Mar 2022

Numinus Gets Approval to Research Ayahuasca & San Pedro

Numinus has just received approval from Health Canada to study Ayahuasca and San Pedro....

By Jason Najum

Industry

8 Mar 2022

Seelos Therapeutics: Year-End Results and Business Highlights

Even if not on most people’s sexiest shroom stock list, Seelos Therapeutics has been a solid presence in the psychedelic medicine space for some time....

By Jason Najum

Don’t Miss

7 Mar 2022

News You Might Have Missed: March 7th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news items to help you catch up and stay informed....

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

2 Mar 2022

MindMed Announces Study Comparing LSD and Psilocybin

Back in the spring of 2020, in the early days of the psychedelic medicine industry, MindMed signed one of the sector's most significant research collaborations....

By Jason Najum

Industry

1 Mar 2022

An Interview With Cybin CEO Doug Drysdale

We sat down with CEO Doug Drysdale to discuss these and other industry topics, including Cybin’s developmental pipeline, upcoming clinical trials, and the state of the psychedelic medicine market...

By Jason Najum

Don’t Miss

28 Feb 2022

News You Might Have Missed: Feb 28th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of news items to help you catch up and stay informed....

By Jason Najum

Finance

23 Feb 2022

A Look at Recent Financial and Business Highlights

To help keep you updated, we’ve put together a summary of recent financial announcements from a variety of psychedelic medicine companies....

By Jason Najum

Don’t Miss

22 Feb 2022

News You Might Have Missed: Feb 22nd, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic news items to help you catch up and stay informed....

By Jason Najum

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.